Featured Tickers:
Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Moderna, Inc., Viridian Therapeutics or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.
Read on to learn how Moderna, Inc., Viridian Therapeutics and Inc. compare based on key financial metrics to determine which better meets your investment needs.
About Moderna, Inc., Viridian Therapeutics and Inc.
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as individualized neoantigen and checkpoint adaptive immune modulation therapy; and rare disease products, including propionic and methylmalonic acidemia, glycogen storage disease type 1a, ornithine transcarbamylase deficiency, phenylketonuria, crigler-najjar syndrome type 1, and cystic fibrosis. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Generation Bio Co.; immatics N.V.; Life Edit Therapeutics; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. The company’s product pipeline includes veligrotug, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R monoclonal antibodies targeting IGF-1R and engineered of half-life extension technology, which is in Phase 3 clinical trial for the treatment of TED. It also develops portfolio of engineered anti-neonatal Fc receptor inhibitors, such as VRDN-006 and VRDN-008 for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.
Latest Biotechnology and Moderna, Inc., Viridian Therapeutics, Inc. Stock News
As of November 6, 2025, Moderna, Inc. had a $9.5 billion market capitalization, compared to the Biotechnology median of $203.9 million. Moderna, Inc.’s stock is down 41% in 2025, down 9.6% in the previous five trading days and down 54.56% in the past year.
Currently, Moderna, Inc. does not have a price-earnings ratio. Moderna, Inc.’s trailing 12-month revenue is $3.1 billion with a -139.6% net profit margin. Year-over-year quarterly sales growth most recently was -41.1%. Analysts expect adjusted earnings to reach $-8.144 per share for the current fiscal year. Moderna, Inc. does not currently pay a dividend.
As of November 6, 2025, Viridian Therapeutics, Inc. had a $2.6 billion market cap, putting it in the 60th percentile of all stocks. Viridian Therapeutics, Inc.’s stock is up 43.1% in 2025, up 16.1% in the previous five trading days and up 20.4% in the past year.
Currently, Viridian Therapeutics, Inc. does not have a price-earnings ratio. Viridian Therapeutics, Inc.’s trailing 12-month revenue is $70.8 million with a -426.6% net profit margin. As of November 6, 2025, Viridian Therapeutics, Inc. has not reported significant year-over-year quarterly sales. Analysts expect adjusted earnings to reach $-4.152 per share for the current fiscal year. Viridian Therapeutics, Inc. does not currently pay a dividend.
How We Compare Moderna, Inc., Viridian Therapeutics and Inc. Stock Grades
Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.
AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Moderna, Inc., Viridian Therapeutics and Inc.’s stock grades to see how they measure up against one another.
Learn more about A+ Investor here!
Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions